INDIVIDUAL DOSE ADAPTATION OF ANTICANCER DRUGS

被引:41
作者
DESOIZE, B [1 ]
ROBERT, J [1 ]
机构
[1] FDN BERGONIE,BIOCHIM LAB,F-33076 BORDEAUX,FRANCE
关键词
ANTICANCER DRUGS; DOSE ADJUSTMENT; NEW THERAPEUTIC STRATEGY; PHARMACOKINETIC; PHARMACOLOGY;
D O I
10.1016/0959-8049(94)90304-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The dose of anticancer drugs is currently adjusted to the patient body surface area, although patients have different abilities to clear anticancer drugs. The dose adjustment to physiological functions permits major toxic accidents to be avoided. The adjustment to tumour drug content is considered, but for ethical or technical reasons, it cannot be used routinely The best criterion for the dose adjustment seems to be drug plasma concentration. The relationship between plasma concentration and efficacy may not be excellent, since it depends on the presence of resistant cells and on the blood how through the tumour. A relationship between plasma concentration and/or the area under the curve (AUC) with toxicity has been reported with all major anticancer drugs. Different methods of dose adjustment to the drug plasma concentration are reported. In conclusion, dose adjustment to the drug plasma concentration or to the AUC can improve the chemotherapy efficacy, while reducing toxicity.
引用
收藏
页码:844 / 851
页数:8
相关论文
共 130 条
  • [11] BORSI JD, 1987, CANCER, V60, P3020, DOI 10.1002/1097-0142(19871215)60:12<3020::AID-CNCR2820601227>3.0.CO
  • [12] 2-0
  • [13] BAYESIAN-ESTIMATION OF DOXORUBICIN PHARMACOKINETIC PARAMETERS
    BRESSOLLE, F
    RAY, P
    JACQUET, JM
    BRES, J
    GALTIER, M
    DONADIO, D
    JOURDAN, J
    ROSSI, JF
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 29 (01) : 53 - 60
  • [14] CLINICAL AND PHARMACOKINETIC STUDY OF 96-H INFUSIONS OF DOXORUBICIN IN ADVANCED CANCER-PATIENTS
    BUGAT, R
    ROBERT, J
    HERRERA, A
    PINEL, MC
    HUET, S
    CHEVREAU, C
    BOUSSIN, G
    ROQUAIN, J
    CARTON, M
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (03): : 505 - 511
  • [15] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION
    CALVERT, AH
    NEWELL, DR
    GUMBRELL, LA
    OREILLY, S
    BURNELL, M
    BOXALL, FE
    SIDDIK, ZH
    JUDSON, IR
    GORE, ME
    WILTSHAW, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1748 - 1756
  • [16] CAMPBELL AB, 1983, CANCER TREAT REP, V67, P169
  • [17] HUMAN PHARMACOKINETICS OF N-L-LEUCYL-DOXORUBICIN, A NEW ANTHRACYCLINE DERIVATIVE, AND ITS CORRELATION WITH CLINICAL TOXICITIES
    CANAL, P
    ROBERT, J
    RAMON, M
    BAURAIN, R
    TRESCA, P
    DEFORNI, M
    MARTY, M
    PUJADELAURAINE, E
    BUGAT, R
    MAGIS, A
    BELPOMME, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (03) : 249 - 259
  • [18] CASPER E, 1989, P AN M AM SOC CLIN, V8, P320
  • [19] COLLERY P, 1990, METAL IONS BIOL MED, V1, P437